Published in Biochemistry on February 13, 1990
"Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A (1993) 2.91
Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol (2007) 2.59
Human anti-self antibodies with high specificity from phage display libraries. EMBO J (1993) 2.08
scFv antibody: principles and clinical application. Clin Dev Immunol (2012) 1.64
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A (1995) 1.46
Computer-aided antibody design. Protein Eng Des Sel (2012) 1.44
A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A (1993) 1.35
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs (2009) 1.30
Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution. Proc Natl Acad Sci U S A (1994) 1.29
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel (2004) 1.25
Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc Natl Acad Sci U S A (1999) 1.18
Genetic fusion of subunits of a dimeric protein substantially enhances its stability and rate of folding. Proc Natl Acad Sci U S A (1993) 1.16
Characterization of a progesterone-binding, three-domain antibody fragment (VH/K) expressed in Escherichia coli. Immunology (1995) 1.16
The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact (2003) 1.07
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A (2014) 1.04
Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol (2006) 0.99
Expression and extracellular release of a functional anti-trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microb Cell Fact (2012) 0.97
Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol (1996) 0.94
Procaryotic expression of single-chain variable-fragment (scFv) antibodies: secretion in L-form cells of Proteus mirabilis leads to active product and overcomes the limitations of periplasmic expression in Escherichia coli. Appl Environ Microbiol (1998) 0.94
The heterodimeric subunit SRP9/14 of the signal recognition particle functions as permuted single polypeptide chain. Nucleic Acids Res (1994) 0.92
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res (2011) 0.90
Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs (2011) 0.90
Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine (Lond) (2012) 0.90
Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys J (1998) 0.88
Construction and characterization of a single-chain catalytic antibody. Proc Natl Acad Sci U S A (1991) 0.84
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel (2012) 0.83
Construction, characterisation and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase. Br J Cancer (1993) 0.82
New binding mode to TNF-alpha revealed by ubiquitin-based artificial binding protein. PLoS One (2012) 0.80
Construction and expression of a bifunctional single-chain antibody against Bacillus cereus p6ores. Appl Environ Microbiol (1998) 0.80
Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Adv Biosci Biotechnol (2013) 0.79
Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model. J Mol Neurosci (2012) 0.77
Expression of a Functional zipFv Antibody Fragment and Its Fusions with Alkaline Phosphatase in the Cytoplasm of an Escherichia coli. Immune Netw (2010) 0.75
Construction and Periplasmic Expression of the Anti-EGFRvIII ScFv Antibody Gene in Escherichia coli. Sci Pharm (2016) 0.75
A current perspective on applications of macrocyclic-peptide-based high-affinity ligands. Biopolymers (2016) 0.75
Screening of human antibody Fab fragment against HBsAg and the construction of its dsFv form. Int J Biol Sci (2008) 0.75
Intracellular immunization of prokaryotic cells against a bacteriotoxin. J Bacteriol (1998) 0.75
Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med (1998) 5.78
In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A (1997) 4.71
In vitro generated antibodies specific for telomeric guanine-quadruplex DNA react with Stylonychia lemnae macronuclei. Proc Natl Acad Sci U S A (2001) 3.97
Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science (1988) 3.38
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol (2000) 2.73
Stability engineering of antibody single-chain Fv fragments. J Mol Biol (2001) 2.58
Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods (1997) 2.44
An in vivo library-versus-library selection of optimized protein-protein interactions. Nat Biotechnol (1999) 2.09
Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol (1999) 2.03
Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal Biochem (1996) 1.94
Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucleic Acids Res (1994) 1.85
Antigen binding forces of individually addressed single-chain Fv antibody molecules. Proc Natl Acad Sci U S A (1998) 1.85
BIACORE analysis of histidine-tagged proteins using a chelating NTA sensor chip. Anal Biochem (1997) 1.79
Sequence statistics reliably predict stabilizing mutations in a protein domain. J Mol Biol (1994) 1.77
The functional expression of antibody Fv fragments in Escherichia coli: improved vectors and a generally applicable purification technique. Biotechnology (N Y) (1991) 1.74
Novel fold and capsid-binding properties of the lambda-phage display platform protein gpD. Nat Struct Biol (2000) 1.71
Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci U S A (1998) 1.69
Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nat Biotechnol (1998) 1.68
Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol (2000) 1.65
Acyl and phosphoryl migration in lysophospholipids: importance in phospholipid synthesis and phospholipase specificity. Biochemistry (1982) 1.53
Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol (2001) 1.53
The Escherichia coli heat shock proteins GroEL and GroES modulate the folding of the beta-lactamase precursor. EMBO J (1990) 1.50
Destabilization of the complete protein secondary structure on binding to the chaperone GroEL. Nature (1994) 1.49
Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry (1992) 1.46
Protein folding in the periplasm of Escherichia coli. Mol Microbiol (1994) 1.46
Selection for improved protein stability by phage display. J Mol Biol (1999) 1.46
An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. Biotechniques (1994) 1.43
Antigen recognition by conformational selection. FEBS Lett (1999) 1.42
In vitro display technologies: novel developments and applications. Curr Opin Biotechnol (2001) 1.40
The precursor of beta-lactamase: purification, properties and folding kinetics. EMBO J (1989) 1.37
Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng (1997) 1.37
High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res (1999) 1.32
Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng (1995) 1.31
Circular beta-lactamase: stability enhancement by cyclizing the backbone. FEBS Lett (1999) 1.30
Crystal structure of the dimeric C-terminal domain of TonB reveals a novel fold. J Biol Chem (2001) 1.30
Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci U S A (2001) 1.26
Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J Mol Biol (1995) 1.24
Filamentous phage infection: crystal structure of g3p in complex with its coreceptor, the C-terminal domain of TolA. Structure (1999) 1.22
Recent advances in producing and selecting functional proteins by using cell-free translation. Curr Opin Biotechnol (1998) 1.21
Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry (1998) 1.20
Effects of overexpressing folding modulators on the in vivo folding of heterologous proteins in Escherichia coli. Curr Opin Biotechnol (1995) 1.18
Cleavage of procaryotically expressed human immunodeficiency virus fusion proteins by factor Xa and application in western blot (immunoblot) assays. J Clin Microbiol (1989) 1.17
Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol (1998) 1.17
An Escherichia coli protein consisting of a domain homologous to FK506-binding proteins (FKBP) and a new metal binding motif. J Biol Chem (1994) 1.16
The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA. II. Isomerase-independent chaperone activity in vitro. J Biol Chem (2000) 1.16
Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng (1997) 1.14
The Escherichia coli SlyD is a metal ion-regulated peptidyl-prolyl cis/trans-isomerase. J Biol Chem (1997) 1.14
Model and simulation of multivalent binding to fixed ligands. Anal Biochem (1998) 1.13
The consequences of stepwise deletions from the signal-processing site of beta-lactamase. J Biol Chem (1987) 1.13
Atomic force microscopy detects changes in the interaction forces between GroEL and substrate proteins. Biophys J (1998) 1.13
Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. Biotechniques (1997) 1.12
Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat Biotechnol (1998) 1.12
Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry (1999) 1.11
Selecting proteins with improved stability by a phage-based method. Nat Biotechnol (1998) 1.10
Functional antibody production using cell-free translation: effects of protein disulfide isomerase and chaperones. Nat Biotechnol (1997) 1.10
A heterodimeric coiled-coil peptide pair selected in vivo from a designed library-versus-library ensemble. J Mol Biol (2000) 1.10
An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett (1998) 1.09
Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry (1998) 1.09
Forces and energetics of hapten-antibody dissociation: a biased molecular dynamics simulation study. J Mol Biol (2001) 1.09
Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J Biol Chem (2000) 1.07
Domain interactions in antibody Fv and scFv fragments: effects on unfolding kinetics and equilibria. FEBS Lett (1999) 1.04
Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J Immunol Methods (1999) 1.04
A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol (1997) 1.03
High enzymatic activity and chaperone function are mechanistically related features of the dimeric E. coli peptidyl-prolyl-isomerase FkpA. J Mol Biol (2001) 1.03
Selecting and evolving functional proteins in vitro by ribosome display. Methods Enzymol (2000) 1.02
Mapping and modification of an antibody hapten binding site: a site-directed mutagenesis study of McPC603. Biochemistry (1991) 1.01
Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p. Gene (1996) 1.00
Affinity and folding properties both influence the selection of antibodies with the selectively infective phage (SIP) methodology. FEBS Lett (1997) 1.00
Refined crystal structure of a recombinant immunoglobulin domain and a complementarity-determining region 1-grafted mutant. J Mol Biol (1992) 0.99
Co-selection of cognate antibody-antigen pairs by selectively-infective phages. FEBS Lett (1995) 0.99
High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl Microbiol Biotechnol (1996) 0.99
The structural basis of phage display elucidated by the crystal structure of the N-terminal domains of g3p. Nat Struct Biol (1998) 0.99
Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J Mol Biol (1999) 0.99
Correctly folded T-cell receptor fragments in the periplasm of Escherichia coli. Influence of folding catalysts. J Mol Biol (1994) 0.98
Thermodynamic partitioning model for hydrophobic binding of polypeptides by GroEL. I. GroEL recognizes the signal sequences of beta-lactamase precursor. J Mol Biol (1994) 0.98
Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem (2001) 0.98
Identification of new tag sequences with differential and selective recognition properties for the anti-FLAG monoclonal antibodies M1, M2 and M5. Mol Divers (1997) 0.98
Activation, aggregation, and product inhibition of cobra venom phospholipase A2 and comparison with other phospholipases. J Biol Chem (1985) 0.97
Glycine to alanine substitutions in helices of glyceraldehyde-3-phosphate dehydrogenase: effects on stability. Biochemistry (1990) 0.97
Expression of functional antibody Fv and Fab fragments in Escherichia coli. Methods Enzymol (1989) 0.97
A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett (1998) 0.96
Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins. Curr Opin Struct Biol (1999) 0.96
Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. Eur J Immunol (1996) 0.96
Thermodynamic partitioning model for hydrophobic binding of polypeptides by GroEL. II. GroEL recognizes thermally unfolded mature beta-lactamase. J Mol Biol (1994) 0.96
Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y) (1993) 0.95
The effect of folding catalysts on the in vivo folding process of different antibody fragments expressed in Escherichia coli. Biotechnology (N Y) (1993) 0.95
The scFv fragment of the antibody hu4D5-8: evidence for early premature domain interaction in refolding. J Mol Biol (2001) 0.95
Signal sequence mutants of beta-lactamase. J Biol Chem (1985) 0.95
Folding nuclei of the scFv fragment of an antibody. Biochemistry (1996) 0.94
The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry (1992) 0.94
Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex. J Mol Biol (2000) 0.94
The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett (1998) 0.94
Secretion and in vivo folding of the Fab fragment of the antibody McPC603 in Escherichia coli: influence of disulphides and cis-prolines. Protein Eng (1991) 0.93
Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems. FEBS Lett (1999) 0.93
GroE prevents the accumulation of early folding intermediates of pre-beta-lactamase without changing the folding pathway. Biochemistry (1992) 0.92
Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain. J Mol Biol (2001) 0.92
Transmission electron microscopy of GroEL, GroES, and the symmetrical GroEL/ES complex. J Struct Biol (1995) 0.90
Selection, characterization and x-ray structure of anti-ampicillin single-chain Fv fragments from phage-displayed murine antibody libraries. J Mol Biol (2001) 0.90
Fast selection of antibodies without antigen purification: adaptation of the protein fragment complementation assay to select antigen-antibody pairs. J Mol Biol (2001) 0.88